US 2014/0370529 A1Published application

Method for diagnosing alzheimer's disease

AssigneesCentre National de la Recherche Scientifique (CNRS), Universite Paris-Sud 11

InventorsMyriam Taverna, Romain Verpillot, Markus Otto, Hans Klafki

Life of this patent

Estimating the term…

Abstract

The present invention relates to a method for diagnosing a neurodegenerative disease in a subject, wherein the level of each of at least two catecholamines is measured in a sample of biological fluid from said subject.

Claims17

Dependent claims

An in vitro method for diagnosing Alzheimer's disease in a subject, comprising the steps of:

a1) measuring the level of each of at least dopamine, adrenaline and noradrenaline in a sample of biological fluid from said subject;
a2) determining a virtual value by combining the levels measured in step a1) applying one of the following algorithms:
V
=
[
i
]
(
[
i
]
+
[
ii
]
+
[
iii
]
)
;
V
=
[
i
]
(
[
ii
]
+
[
iii
]
)
;
V
=
[
ii
]
(
[
i
]
+
[
ii
]
+
[
iii
]
)
;
V
=
[
ii
]
(
[
i
]
+
[
iii
]
)
;
V
=
[
iii
]
(
[
i
]
+
[
ii
]
+
[
iii
]
)
;
V
=
[
iii
]
(
[
i
]
+
[
ii
]
)
;
V
=
(
[
i
]
+
[
ii
]
)
(
[
i
]
+
[
ii
]
+
[
iii
]
)
;
V
=
(
[
i
]
+
[
ii
]
)
(
[
ii
]
+
[
iii
]
)
;
V
=
(
[
i
]
+
[
ii
]
)
(
[
i
]
+
[
iii
]
)
;
V
=
(
[
i
]
+
[
ii
]
)
[
iii
]
;
V
=
(
[
i
]
+
[
iii
]
)
(
[
i
]
+
[
ii
]
+
[
iii
]
)
;
V
=
(
[
i
]
+
[
iii
]
)
(
[
ii
]
+
[
iii
]
)
;
V
=
(
[
i
]
+
[
iii
]
)
(
[
ii
]
+
[
i
]
)
;
V
=
(
[
i
]
+
[
iii
]
)
[
ii
]
;
V
=
(
[
ii
]
+
[
iii
]
)
(
[
i
]
+
[
ii
]
+
[
iii
]
)
;
V
=
(
[
ii
]
+
[
iii
]
)
(
[
i
]
+
[
iii
]
)
;
V
=
(
[
ii
]
+
[
iii
]
)
(
[
i
]
+
[
ii
]
)
;
V
=
(
[
ii
]
+
[
iii
]
)
[
i
]
;
or
V
=
[
i
]
+
[
ii
]
+
[
iii
]
;
wherein V is the virtual value to be determined and [x] is the respective level of one of said dopamine, adrenaline and noradrenaline, x being i, ii or iii.;
and
b) based on the virtual value determined in step a2), determining whether said subject suffers from Alzheimer's disease;
or
a′1) measuring the global level of at least two catecholamines in a sample of biological fluid from said subject;
and
b′) based on the global level measured in step a′1), determining whether said subject suffers from Alzheimer's disease.

369 more elements

A method for the therapeutic follow-up of a treatment against Alzheimer's disease of a subject, comprising the steps of:

a1) measuring the level of each of at least dopamine, adrenaline and noradrenaline in a sample of biological fluid from said subject before the treatment;
a2) determining a first virtual value by combining the levels measured in step a1) applying one of the following algorithms:
V
=
[
i
]
(
[
i
]
+
[
ii
]
+
[
iii
]
)
;
V
=
[
i
]
(
[
ii
]
+
[
iii
]
)
;
V
=
[
ii
]
(
[
i
]
+
[
ii
]
+
[
iii
]
)
;
V
=
[
ii
]
(
[
i
]
+
[
iii
]
)
;
V
=
[
iii
]
(
[
i
]
+
[
ii
]
+
[
iii
]
)
;
V
=
[
iii
]
(
[
i
]
+
[
ii
]
)
;
V
=
(
[
i
]
+
[
ii
]
)
(
[
i
]
+
[
ii
]
+
[
iii
]
)
;
V
=
(
[
i
]
+
[
ii
]
)
(
[
ii
]
+
[
iii
]
)
;
V
=
(
[
i
]
+
[
ii
]
)
(
[
i
]
+
[
iii
]
)
;
V
=
(
[
i
]
+
[
ii
]
)
[
iii
]
;
V
=
(
[
i
]
+
[
iii
]
)
(
[
i
]
+
[
ii
]
+
[
iii
]
)
;
V
=
(
[
i
]
+
[
iii
]
)
(
[
ii
]
+
[
iii
]
)
;
V
=
(
[
i
]
+
[
iii
]
)
(
[
ii
]
+
[
i
]
)
;
V
=
(
[
i
]
+
[
iii
]
)
[
ii
]
;
V
=
(
[
ii
]
+
[
iii
]
)
(
[
i
]
+
[
ii
]
+
[
iii
]
)
;
V
=
(
[
ii
]
+
[
iii
]
)
(
[
i
]
+
[
iii
]
)
;
V
=
(
[
ii
]
+
[
iii
]
)
(
[
i
]
+
[
ii
]
)
;
V
=
(
[
ii
]
+
[
iii
]
)
[
i
]
;
or
V
=
[
i
]
+
[
ii
]
+
[
iii
]
;
wherein V is the virtual value to be determined and [x] is the respective level of one of said dopamine, adrenaline and noradrenaline, x being i, ii or iii;
b1) measuring the level of each of said at least dopamine, adrenaline and noradrenaline in a sample of biological fluid from said subject during or after the treatment;
b2) determining a second virtual value by combining the levels measured in step b1) applying one of the following algorithms:
V
=
[
i
]
(
[
i
]
+
[
ii
]
+
[
iii
]
)
;
V
=
[
i
]
(
[
ii
]
+
[
iii
]
)
;
V
=
[
ii
]
(
[
i
]
+
[
ii
]
+
[
iii
]
)
;
V
=
[
ii
]
(
[
i
]
+
[
iii
]
)
;
V
=
[
iii
]
(
[
i
]
+
[
ii
]
+
[
iii
]
)
;
V
=
[
iii
]
(
[
i
]
+
[
ii
]
)
;
V
=
(
[
i
]
+
[
ii
]
)
(
[
i
]
+
[
ii
]
+
[
iii
]
)
;
V
=
(
[
i
]
+
[
ii
]
)
(
[
ii
]
+
[
iii
]
)
;
V
=
(
[
i
]
+
[
ii
]
)
(
[
i
]
+
[
iii
]
)
;
V
=
(
[
i
]
+
[
ii
]
)
[
iii
]
;
V
=
(
[
i
]
+
[
iii
]
)
(
[
i
]
+
[
ii
]
+
[
iii
]
)
;
V
=
(
[
i
]
+
[
iii
]
)
(
[
ii
]
+
[
iii
]
)
;
V
=
(
[
i
]
+
[
iii
]
)
(
[
ii
]
+
[
i
]
)
;
V
=
(
[
i
]
+
[
iii
]
)
[
ii
]
;
V
=
(
[
ii
]
+
[
iii
]
)
(
[
i
]
+
[
ii
]
+
[
iii
]
)
;
V
=
(
[
ii
]
+
[
iii
]
)
(
[
i
]
+
[
iii
]
)
;
V
=
(
[
ii
]
+
[
iii
]
)
(
[
i
]
+
[
ii
]
)
;
V
=
(
[
ii
]
+
[
iii
]
)
[
i
]
;
or
V
=
[
i
]
+
[
ii
]
+
[
iii
]
;
wherein V is the virtual value to be determined and [x] is the respective level of one of said dopamine, adrenaline and noradrenaline, x being i, ii or iii.;
and
c) based on the first and second virtual values respectively determined in steps a2) and b2), determining whether said subject benefits from said treatment against Alzheimer's disease;
or
a′) measuring a first global level of at least two catecholamines in a sample of biological fluid from said subject before the treatment;
b′) measuring a second global level of said at least two catecholamines in a sample of biological fluid from said subject during or after the treatment;
and
c′) based on the first and second global levels respectively determined in steps a′) and b′), determining whether said subject benefits from said treatment against Alzheimer's disease.

736 more elements

Dependencies are inferred from the claim text.

Facts

Application: 14/345,179Filed 17 Sep 2012
Priority: EP 11306171.716 Sep 2011
Published: 18 Dec 2014
Term ends: Not estimatedThe source records don’t support an estimate.

Classification5 codes

G01N 33/54306
With an insoluble carrier for immobilising immunochemicals: solid-phase reaction mechanisms
G01N 33/6896
Related to diseases not provided for elsewhere: neurological disorders, e.g. Alzheimer's disease
G01N 2800/2821
Dementia; Cognitive disorders: alzheimer
G01N 2800/52
Detection or diagnosis of diseases: predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in…

Family

US 9,606,113 B2Related patent
US 2014/0370529 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

Facts

Application

14/345,179Filed 17 Sep 2012

Priority

EP 11306171.716 Sep 2011

Published

18 Dec 2014

Term ends

Not estimatedThe source records don’t support an estimate.

Classification5 codes

G01N 33/54306
With an insoluble carrier for immobilising immunochemicals: solid-phase reaction mechanisms
G01N 33/6896
Related to diseases not provided for elsewhere: neurological disorders, e.g. Alzheimer's disease
G01N 2800/2821
Dementia; Cognitive disorders: alzheimer
G01N 2800/52
Detection or diagnosis of diseases: predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in…